Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15907176 | 0.86 | KMT2A (0.61) | LMNAALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3839084 | 0.83 | TDP1 (0.52) | ALDH1A1MEN1KMT2ATDP1RAB9A | |
| SCHEMBL16954029 | 0.83 | CA12 (0.41) | LMNAMEN1KMT2ATDP1RAB9A | |
| SCHEMBL8615592 | 0.83 | ACACB (0.57) | LMNAALDH1A1MEN1KMT2AACACB | |
| SCHEMBL15907199 | 0.82 | HDAC3 (0.60) | ALDH1A1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL5389398 | 0.82 | MEN1 (0.50) | LMNAALDH1A1MEN1KMT2AACACB | |
| Acetophenone SCHEMBL27862447 | 0.82 | SMN1; SMN2 (0.52) | LMNAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL256865 | 0.82 | CA12 (0.52) | KMT2AHPGDCA12CA1CA2 | |
| SCHEMBL29411053 | 0.82 | CA12 (0.52) | KMT2AHPGDCA12CA1CA2 | |
| SCHEMBL1568517 | 0.80 | PARP1 (0.53) | MEN1KMT2ATDP1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118240199-B | Binuclear copper complex based on alkyne palladium ligand and preparation method thereof | 安徽大学 | 2024-10-11 | — | — | CN | disclosed |
| CN-114450271-B | Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition | 纽力克斯治疗公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118240199-A | Binuclear copper complex based on alkyne palladium ligand and preparation method thereof | 安徽大学 | 2024-06-25 | — | — | CN | disclosed |
| WO-2023051628-A1 | SOS1 INHIBITORS HAVING PYRIDO SIX-MEMBERED RING STRUCTURE | 上海海和药物研究开发股份有限公司 | 2023-04-06 | — | — | WO | disclosed |
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-111517902-B | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2022-06-14 | — | — | CN | disclosed |
| EP-4003965-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | Nurix Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450271-A | Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition | 纽力克斯治疗公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-0975573-B1 | TRISUBSTITUTED PHENYL DERIVATIVES HAVING RETINOID AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY | ALLERGAN SALES INC (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | disclosed |
| US-6235923-B1 | RETINOIDS AND CELL DIFFERENTIATION | ALLERGAN SALES, INC. | 2001-05-22 | — | — | US | disclosed |
| US-6225494-B1 | TREATING SKIN DISORDERS, REDUCED SIDE EFFECTS | ALLERGAN SALES, INC. | 2001-05-01 | — | — | US | disclosed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | disclosed |
| US-6037488-A | COMPOUNDS SUCH AS 4-((4'-ISOPROPOXY-3'-(1-M-TOLYL)VINYL)PHENYLETHYNYL)BENZOIC ACID | ALLERGAN SALES, INC. (US) | 2000-03-14 | — | — | US | disclosed |
| EP-0975573-A1 | TRISUBSTITUTED PHENYL DERIVATIVES HAVING RETINOID AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY | Allergan Sales, Inc. (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047854-A1 | TRISUBSTITUTED PHENYL DERIVATIVES HAVING RETINOID AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 1998-10-29 | — | — | WO | disclosed |
| US-5202349-A | Lipoxygenase inhibitors, antiasthatics | GRUENENTHAL GMBH (DE) | 1993-04-13 | — | — | US | disclosed |
| US-4120909-A | DEHYDRATION OF METHYL PHENYL KETONES, CATALYST | HERCULES INCORPORATED (US) | 1978-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | CBLB, CBL, CBLC | LMNA 2705/4885ALDH1A1 4274/4885MEN1 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.